definiens: shall mean any and all losses, damages, liabilities, costs and expenses ( including without limitationreasonable legal fees and expenses ) taking account of the duty on the Party suffering such Losses tomitigate such Losses ; 1.49 shall mean all activities relating to making / or having made the API and/or the Drug Productand all associated activities including labelling / or having labelled, and packaging or having packaged the DrugProduct in accordance with GMP ; 1.50 shall mean the plan for manufacture of the API and the Drug Product andits supply to the DNDi Territory and to the Entasis Territory to be developed and by the Parties in accordancewith Clause 6 ; 1.51 shall mean all approval(s ), registration(s ) and authorisation(s ) necessary to beobtained from an applicable Drug Regulatory Authority to lawfully import, promote, distribute and sell theProduct in the Field in a country of the DNDi Territory or the Entasis Territory, as applicable ; 1.52 shall have the meaning set out in the recitals ; 1.53 shall have the meaning set out in Clause 5.8 ; 1.54 shall mean any : ( i ) patents and patent applications ( provisional and non - provisional);(ii ) continuations, divisionals, continuations - in - part, continued prosecutions, re - examinations, reissues, utilitymodels, petty and other patent applications claiming subject matter therein or claiming priority from any of theforegoing, and all patents that issue there from ; ( iii ) counterparts, substitutions, restorations, extensions(including, without limitation, patent term extensions ), supplementary protection certificates, registrations, confirmations, validations and renewals of any of the foregoing ; and ( iv ) invention certificates and othergovernment grants for the protection of inventions or industrial designs ; 1.55 shall have the meaning set out in Clause 9.2 ; 5 | Page [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filedseparately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, asamended